Hacker News Reader

> Also what would be the bad outcomes here? If those drugs end up not being safe (that is prevented by the requirement to not withhold safety data), or being effective?

Barring a time machine, safety data reporting is gonna lag at least some of the bad outcomes.

View on HN

That is the same with all post-market monitoring for drugs. And maybe we can do better because more nimble/startup approach in a small state

Isn't this pre-market, though?

Relative to the federal approval it's pre-market. In Montana, if your treatment is approved by a review board it's in market

But there are, obviously, proportionally way fewer bad outcomes created by drugs that pass Phases 2 and 3 than those that only pass Phase 1. The steepness of that attrition is literally the entire value prop of the law to begin with.

Reply on news.ycombinator.com